C-Path welcomes Sanofi to its Type 1 Diabetes Consortium to help advance drug development
TUCSON, Ariz., August 9, 2023 — Critical Path Institute (C-Path) announced today that Sanofi, a global leader in immunology and diabetes care, has joined its Type 1 Diabetes Consortium (T1DC). Sanofi joins T1DC as part of its commitment to push the boundaries of innovation to improve the lives of those with diabetes.
T1DC was established in 2017 with the goal to significantly advance the drug development landscape for T1D prevention and treatment. The consortium achieves this by fostering ...














